TY - JOUR
T1 - TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia
AU - Yu, Jianhua
AU - Ershler, Maxim
AU - Yu, Li
AU - Wei, Min
AU - Hackanson, Björn
AU - Yokohama, Akihiko
AU - Mitsui, Takeki
AU - Liu, Chunhui
AU - Mao, Hsiaoyin
AU - Liu, Shujun
AU - Liu, Zhongfa
AU - Trotta, Rossana
AU - Liu, Chang Gong
AU - Liu, Xiuping
AU - Huang, Kun
AU - Visser, Jan
AU - Marcucci, Guido
AU - Plass, Christoph
AU - Belyavsky, Alexander V.
AU - Caligiuri, Michael A.
PY - 2009
Y1 - 2009
N2 - Aberrant methylation of tumor suppressor genes can lead to their silencing in many cancers. TSC-22 is a gene silenced in several solid tumors, but its function and the mechanism(s) responsible for its silencing are largely unknown. Here we demonstrate that the TSC-22 promoter is methylated in primary mouse T or natural killer (NK) large granular lymphocyte (LGL) leukemia and this is associated with down-regulation or silencing of TSC-22 expression. The TSC-22 deregulation was reversed in vivo by a 5-aza-2′-deoxycytidine therapy of T or NK LGL leukemia, which significantly increased survival of the mice bearing this disease. Ectopic expression of TSC-22 in mouse leukemia or lymphoma cell lines resulted in delayed in vivo tumor formation. Targeted disruption of TSC-22 in wild-type mice enhanced proliferation and in vivo repopulation efficiency of hematopoietic precursor cells (HPCs). Collectively, our data suggest that TSC-22 normally contributes to the regulation of HPC function and is a putative tumor suppressor gene that is hypermethylated and silenced in T or NK LGL leukemia.
AB - Aberrant methylation of tumor suppressor genes can lead to their silencing in many cancers. TSC-22 is a gene silenced in several solid tumors, but its function and the mechanism(s) responsible for its silencing are largely unknown. Here we demonstrate that the TSC-22 promoter is methylated in primary mouse T or natural killer (NK) large granular lymphocyte (LGL) leukemia and this is associated with down-regulation or silencing of TSC-22 expression. The TSC-22 deregulation was reversed in vivo by a 5-aza-2′-deoxycytidine therapy of T or NK LGL leukemia, which significantly increased survival of the mice bearing this disease. Ectopic expression of TSC-22 in mouse leukemia or lymphoma cell lines resulted in delayed in vivo tumor formation. Targeted disruption of TSC-22 in wild-type mice enhanced proliferation and in vivo repopulation efficiency of hematopoietic precursor cells (HPCs). Collectively, our data suggest that TSC-22 normally contributes to the regulation of HPC function and is a putative tumor suppressor gene that is hypermethylated and silenced in T or NK LGL leukemia.
UR - http://www.scopus.com/inward/record.url?scp=67049137380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67049137380&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-02-205732
DO - 10.1182/blood-2009-02-205732
M3 - Article
C2 - 19329776
AN - SCOPUS:67049137380
SN - 0006-4971
VL - 113
SP - 5558
EP - 5567
JO - Blood
JF - Blood
IS - 22
ER -